Table 2 Summary of total number of labeled standard analytes which experienced matrix effect (suppression or enhancement) from plasma vs. serum
| Â | HILIC | C18 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Â | MeOH | MeOH:ACN | ACN | Hybrid-SPE/ACN | Hybrid-SPE/MeOH | MeOH | MeOH:ACN | ACN | Hybrid-SPE/ACN | Hybrid-SPE/MeOH |
Plasma | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
 Suppressed (+ESI) | 2 | 3 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 1 |
 Enhanced (+ESI) | 1 | 0 | 3 | 0 | 0 | 4 | 2 | 3 | 4 | 2 |
 Total affected (+ESI) | 3 | 3 | 3 | 1 | 2 | 4 | 2 | 3 | 0 | 3 |
 Total unaffected (+ESI) | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 1 |
 Suppressed (− ESI) | 3 | 0 | 0 | 1 | 6 | 1 | 0 | 1 | 0 | 1 |
 Enhanced (− ESI) | 1 | 2 | 5 | 3 | 0 | 0 | 2 | 1 | 3 | 1 |
 Total affected (− ESI) | 4 | 2 | 5 | 4 | 6 | 1 | 2 | 2 | 3 | 2 |
 Total unaffected (− ESI) | 2 | 3 | 0 | 2 | 0 | 3 | 2 | 0 | 0 | 2 |
Serum | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
 Suppressed (+ESI) | 0 | 0 | 1 | 0 | 2 | 1 | 0 | 0 | 0 | 3 |
 Enhanced (+ESI) | 1 | 1 | 1 | 3 | 0 | 1 | 4 | 4 | 1 | 1 |
 Total affected (+ESI) | 1 | 1 | 2 | 3 | 2 | 2 | 4 | 4 | 1 | 4 |
 Total unaffected (+ESI) | 2 | 1 | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
 Suppressed (− ESI) | 1 | 0 | 0 | 3 | 2 | 2 | 1 | 1 | 0 | 2 |
 Enhanced (− ESI) | 5 | 6 | 6 | 3 | 0 | 1 | 2 | 2 | 3 | 0 |
 Total affected (− -ESI) | 6 | 6 | 6 | 6 | 2 | 3 | 3 | 3 | 3 | 2 |
 Total unaffected (− ESI) | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |